WO2023042096 - FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE
National phase entry:
Publication Number
WO/2023/042096
Publication Date
23.03.2023
International Application No.
PCT/IB2022/058670
International Filing Date
14.09.2022
Title **
[English]
FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE
[French]
ADMINISTRATION FACILITÉE DE FORMULATIONS D'ANTICORPS CONCENTRÉES À L'AIDE D'HYALURONIDASE
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
1-1 Doshomachi 4-Chome, Chuo-Ku, Osaka-shi
Osaka 541-0045, JP
Inventors
HOEFINGHOFF, Joris
Guglgasse 8/2/38
1110 Vienna, AT
LEIDENMUEHLER, Peter
Friedrich-Engels-Platz 15-16/1/26
1200 Vienna, AT
GANGADHARAN, Bagirath
26, Favoritenstrasse, 4B
1040 Vienna, AT
HAIDER, Norbert
Loewengasse 11/9
1030 Vienna, AT
NAGY, Andras
c/o Baxalta Innovations GmbH
Industriestrasse 67
1220 Vienna, AT
LI, Zhaoyang
75 Albemarle Rd.
Newton, Massachusetts 02460, US
Priority Data
63/243,832
14.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3208 | |
| EPO | Filing, Examination | 14920 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 6660 |
Total: 25957 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided is a concentrated pharmaceutical formulation of an immune globulin (IG), and convenient methods for the subcutaneous administration of this pharmaceutical formulation in a warmed state. Such products can be used in methods of treating IG-treatable diseases or conditions. Also provided are combinations, compositions and kits containing an immune globulin (IG) composition and a soluble hyaluronidase composition formulated for subcutaneous administration.[French]
L'invention concerne une formulation pharmaceutique concentrée d'une immunoglobuline (IG), et des méthodes pratiques pour l'administration sous-cutanée de cette formulation pharmaceutique dans un état chauffé. De tels produits peuvent être utilisés dans des méthodes de traitement de maladies ou d'affections pouvant être traitées par IG. L'invention concerne également des combinaisons, des compositions et des kits contenant une composition d'immunoglobuline (IG) et une composition d'hyaluronidase soluble formulée pour une administration sous-cutanée.